BR112023025880A2 - Formulação subcutânea e métodos para tratamento de edema refratário a diuréticos orais - Google Patents
Formulação subcutânea e métodos para tratamento de edema refratário a diuréticos oraisInfo
- Publication number
- BR112023025880A2 BR112023025880A2 BR112023025880A BR112023025880A BR112023025880A2 BR 112023025880 A2 BR112023025880 A2 BR 112023025880A2 BR 112023025880 A BR112023025880 A BR 112023025880A BR 112023025880 A BR112023025880 A BR 112023025880A BR 112023025880 A2 BR112023025880 A2 BR 112023025880A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- treatment
- subcutaneous formulation
- oral diuretics
- refractory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208863P | 2021-06-09 | 2021-06-09 | |
| PCT/US2022/032862 WO2022261344A1 (en) | 2021-06-09 | 2022-06-09 | Subcutaneous formulation and methods for treating edema refractory to oral diuretics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025880A2 true BR112023025880A2 (pt) | 2024-02-27 |
Family
ID=84425561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025880A BR112023025880A2 (pt) | 2021-06-09 | 2022-06-09 | Formulação subcutânea e métodos para tratamento de edema refratário a diuréticos orais |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240285566A1 (https=) |
| EP (1) | EP4351554A4 (https=) |
| JP (1) | JP2024520788A (https=) |
| KR (1) | KR20240042402A (https=) |
| CN (1) | CN117915905A (https=) |
| AU (1) | AU2022289724A1 (https=) |
| BR (1) | BR112023025880A2 (https=) |
| CA (1) | CA3221710A1 (https=) |
| IL (1) | IL309160A (https=) |
| WO (1) | WO2022261344A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293429A (en) | 2019-12-04 | 2022-07-01 | RESQ Pharmaceuticals LLC | Methods and preparations for the treatment of edema resistant to oral diuretics |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040105818A1 (en) * | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
| US7906555B2 (en) * | 2006-10-26 | 2011-03-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
| US20140128469A1 (en) * | 2011-05-10 | 2014-05-08 | Concert Pharmaceuticals Inc. | Deuterated n-butyl bumetanide |
| US20210163406A1 (en) * | 2018-04-06 | 2021-06-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs |
| IL293429A (en) * | 2019-12-04 | 2022-07-01 | RESQ Pharmaceuticals LLC | Methods and preparations for the treatment of edema resistant to oral diuretics |
-
2022
- 2022-06-09 JP JP2023575713A patent/JP2024520788A/ja active Pending
- 2022-06-09 EP EP22821041.5A patent/EP4351554A4/en active Pending
- 2022-06-09 CA CA3221710A patent/CA3221710A1/en active Pending
- 2022-06-09 IL IL309160A patent/IL309160A/en unknown
- 2022-06-09 KR KR1020247000323A patent/KR20240042402A/ko active Pending
- 2022-06-09 BR BR112023025880A patent/BR112023025880A2/pt not_active Application Discontinuation
- 2022-06-09 CN CN202280053609.8A patent/CN117915905A/zh active Pending
- 2022-06-09 AU AU2022289724A patent/AU2022289724A1/en active Pending
- 2022-06-09 US US18/568,440 patent/US20240285566A1/en active Pending
- 2022-06-09 WO PCT/US2022/032862 patent/WO2022261344A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL309160A (en) | 2024-02-01 |
| KR20240042402A (ko) | 2024-04-02 |
| CA3221710A1 (en) | 2022-12-15 |
| WO2022261344A1 (en) | 2022-12-15 |
| EP4351554A4 (en) | 2025-05-07 |
| AU2022289724A1 (en) | 2024-01-18 |
| JP2024520788A (ja) | 2024-05-24 |
| US20240285566A1 (en) | 2024-08-29 |
| EP4351554A1 (en) | 2024-04-17 |
| CN117915905A (zh) | 2024-04-19 |
| WO2022261344A8 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230190A1 (ar) | مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس | |
| CO2021015318A2 (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| BR112022010879A2 (pt) | Métodos e composições para tratamento de edema refratário a diuréticos orais | |
| BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
| BR112022008294A2 (pt) | Composições de profármaco e métodos de tratamento | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| CL2019001658A1 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| BR112018000786A2 (pt) | métodos e composições usando bifidobacterium longum para modular a reatividade emocional e tratar ou evitar perturbações subclínicas do estado de humor | |
| MX2024008115A (es) | Tratamiento conjunto para tratamiento contra el cancer. | |
| BR112018016349A2 (pt) | métodos para tratamento e profilaxia de hiv e aids | |
| MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| CL2022002531A1 (es) | Moduladores de nlrp3 | |
| BR112022017491A2 (pt) | Método para tratar indivíduos resistentes ao inibidor idh1 | |
| BR112022012917A2 (pt) | Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica | |
| CO2021000229A2 (es) | Compuestos de pirazol e imidazol para la inhibición de il-17 y rorgamma | |
| BR112023025880A2 (pt) | Formulação subcutânea e métodos para tratamento de edema refratário a diuréticos orais | |
| BR112022017466A2 (pt) | Terapia combinada com um inibidor de idh mutante e um inibidor de bcl-2 | |
| BR112022016045A2 (pt) | Composto de óxido de fosfina quinolina, e composição e aplicação do mesmo. | |
| BR112022019338A2 (pt) | Tratamento preventivo de enxaqueca | |
| BR112021010856A2 (pt) | Vibegron para o tratamento de sintomas de bexiga hiperativa | |
| BR112022020012A2 (pt) | Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2841 DE 17/06/2025 POR TER SIDO INDEVIDA. |